Zhou2007 - Polyreactive Antibodies Natural Antibody Function

Full citation: Zhou ZH, Tzioufas AG, Notkins AL. “Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells.” Journal of Autoimmunity 2007; 29(4):219–228. DOI: 10.1016/j.jaut.2007.07.015.

Raw file: [[raw/Zhou2007.pdf]]

Summary

This NIH (Notkins lab) review summarises several decades of experimental work on polyreactive antibodies — immunoglobulin molecules that bind to multiple structurally unrelated self and non-self antigens. Originally discovered in virus-infected and normal mice via hybridoma technology, polyreactive antibodies were subsequently found in all jawed vertebrates (human to shark), indicating they are an ancient and conserved feature of the immune repertoire. The review characterises their properties, the B cell populations that produce them (PAB cells), and their functional role in broad antibacterial innate defence.

A central argument is that polyreactivity — self-reactivity of this type — is a normal feature of the immune system, not a pathological one. The key distinction drawn is between naturally occurring low-affinity, germline, primarily IgM polyreactive antibodies and the high-affinity, somatically mutated, IgG/IgA autoantibodies that drive autoimmune disease. The paper also proposes that PAB cells may contribute to immune tolerance by presenting self-antigens to T cells in the absence of co-stimulatory signals.

Study Design

• Type: Narrative review (presented at “Autoimmunity: Physiological and Pathophysiological Aspects,” Athens, May 2007)
• Sample size: N/A (review of prior hybridoma and flow cytometry studies)
• Setting: NIH (National Institute of Dental and Craniofacial Research), Bethesda, USA; primarily murine models with some human data
• Population: Mouse (hybridoma, peritoneal cavity, spleen) and human (cord blood, adult peripheral blood B cells)

Key Findings

• Polyreactive antibodies bind structurally diverse antigens — including proteins, DNA, LPS, haptens — through flexible antigen-binding pockets (germline-encoded, low affinity: Kd 10⁻⁴–10⁻⁷ mol L⁻¹ vs. 10⁻⁷–10⁻¹¹ for monoreactive antibodies)
• Predominantly IgM but some IgA and IgG; germline or near-germline sequence (little to no somatic hypermutation)
• Extremely short half-lives compared to monoreactive antibodies: IgM ~8 h vs. ~35 h; IgA ~8 h vs. ~26 h; IgG ~10 h vs. ~280 h — thought to reflect rapid binding to endogenous host antigens in circulation
• Low circulating concentration because most polyreactive IgM is already bound to serum proteins; affinity purification to dissociate bound antigens reveals substantial polyreactivity in normal human sera
• PAB (polyreactive antigen-binding B) cells constitute ~50% of B cells in cord blood and 15–20% of adult peripheral blood B cells; widely distributed (Peyer’s patches, lamina propria, splenic marginal zone, thymus)
• PAB cells overlap with but are not confined to the B-1 subset: only 34% of peritoneal PAB⁺ cells are CD5⁺; only 3.6% of splenic PAB⁺ cells are CD5⁺ — the two populations are distinct
• Antibacterial function demonstrated: monoclonal polyreactive antibody PAb2E4 (IgM) fixes complement and lyses Gram-negative bacteria; enhances macrophage phagocytosis; generates anaphylatoxin C5a against Gram-positive bacteria; polyreactive-enriched human IgM also lysed E. coli in complement lysis assays — explaining the “natural antibody” antibacterial activity long seen in sera of newborns and germ-free animals
• Polyreactive antibodies found in all jawed vertebrates examined — from humans to sharks — indicating evolutionary conservation since the origin of the adaptive immune system
• Possible tolerance role: PAB cells are proposed to present self-antigens to T cells without activating co-stimulatory molecules B7-1/B7-2, potentially inducing or maintaining peripheral immune tolerance

Methods Used

• Hybridoma Technology
• ELISA (antigen-binding panel characterisation)
• Flow Cytometry (FACS; PAB cell identification, B cell subset phenotyping)
• Bacterial lysis assays (³H-thymidine incorporation, ³H-TdR release)
• Antigen-coated magnetic bead separation (PAB⁺/PAB⁻ cell isolation)

Entities Mentioned

• No dengue-specific entities.

Concepts Addressed

• Polyreactive Antibodies
• Infection-Triggered Autoimmunity
• Antinuclear Antibodies
• Autoimmunity in Dengue

Relevance & Notes

This paper does not study dengue directly. Its relevance to this wiki is as a mechanistic interpretive framework for a persistent puzzle: why do acute viral infections — including dengue — produce massive elevations in broad antinuclear reactivity (54.8% IIFA in Chatterjee2024 - ANA Detection in Dengue Kolkata; 80 IgM autoantibodies elevated in Vo2020 - Autoantibody Profiling in Dengue) that are mostly non-specific (LIA-negative in ~66% of IIFA-positives)?

The polyreactive antibody framework offers a mechanistically grounded explanation: many of these IgM “autoantibodies” may not represent induced autoimmunity at all. They may be the normal, short-lived, germline-encoded polyreactive IgM that is always present in circulation at low levels — activated or transiently expanded during dengue’s cytokine milieu, then rapidly cleared (half-life ~8h). This would explain their non-specific pattern, their IgM dominance, their failure to confirm on LIA (which tests specific disease-associated autoantibodies), and the apparent paradox that most dengue patients with elevated IIFA do not progress to clinical autoimmune disease.

This interpretation requires caution: it does not explain away the specific pathogenic autoantibodies well-documented in this wiki (anti-platelet IgM via NS1 molecular mimicry, Lin2001; anti-endothelial autoantibodies, Lin2006). Those involve affinity-matured, antigen-driven responses to defined epitopes and are clinically consequential. The polyreactive framework applies most cleanly to the non-specific LIA-negative IIFA fraction — not to the disease-specific autoantibodies.

The paper also provides important conceptual grounding for the Berlin2007 finding that ANA jumps to 21.7% during acute viral infections: this elevation may partly reflect polyreactive IgM activation rather than de novo induction of autoimmunity by each specific virus.

Limitation: All mechanistic data are from murine hybridoma experiments or human B cell studies in vitro. No dengue patient samples were studied. The half-life data are from mouse experiments; human polyreactive IgM half-life data were inferred from affinity purification of human sera (ref [13]) rather than direct kinetic measurement.

Questions Raised

• Does dengue specifically expand the polyreactive IgM pool (via TLR4 activation, bystander B cell stimulation) beyond baseline, or does it merely unmask pre-existing circulating polyreactive IgM by releasing bound antigens (tissue damage releasing proteins that had been sequestered)?
• Can the IIFA-positive, LIA-negative dengue ANA fraction be definitively characterised as polyreactive (IgM dominant, germline V-region usage, low affinity) vs. antigen-specifically induced, by sequencing the BCRs of the IIFA-positive B cells in a dengue patient cohort?
• If dengue PAB cell expansion is transient and these cells do not survive to convalescence (consistent with the Sungnak2025 finding of convalescence-absent plasmablast clonotype), what accounts for the 23.1% ANA positivity at 2 years post-dengue in Garcia2009?